Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Nasdaq100 ETF — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Nasdaq100 ETF trades at $720.68 (market cap $501.32B). The key difference: Nasdaq100 ETF is far larger — about 56.5× Kymera Therapeutics Inc. Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is more actively traded (779,107 versus 28,524,918). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Nasdaq100 ETF for 163 Days on average.
| KYMR | QQQ | |
|---|---|---|
Market Cap | $8.87B | $501.32B |
Volume | 779,107 | 28,524,918 |
Sector | Health | — |
52-Week High | $127.31 | $759.66 |
52-Week Low | $55.80 | $558.34 |
Typical Hold Time | 0 Days | 163 Days |
Enterprise Value | $8.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QQQ trades at $728.95, down 2.28% today amid broader market pressure. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. The ETF faces mixed analyst sentiment with a 50/50 split between buy and sell recommendations. Recent news highlights concerns about AI market sustainability and Fed rate impacts, though historical patterns suggest potential post-midterm election strength.
QQQ's concentrated tech exposure offers growth potential through AI-driven innovation but carries valuation risks amid elevated market levels. Key risks include interest rate sensitivity and sector concentration, while institutional expansion through new international ETFs signals long-term confidence in the innovation theme.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
